Đang chuẩn bị liên kết để tải về tài liệu:
Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

Nivolumab has changed the treatment of advanced gastric cancer (AGC). Nivolumab shows better outcomes compared to best supportive care among AGC patients who received at least two prior regimens. | Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses

TÀI LIỆU LIÊN QUAN

A review of manufacture, bioavailability, safety and clinical efficacy of milk thistle phytosome

Efficacy and safety of terbinafine in the treatment of dermatophytosis at Nghean provincipal leprosy, dermatology centre (2015-2016)

Báo cáo khoa học: "The Safety and efficacy of a new self-expandable intratracheal nitinol stent for the tracheal collapse in dogs"

Báo cáo y học: " Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial"

Báo cáo y học: "Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review"

Báo cáo khoa học: "The safety and efficacy of gamma knife surgery in management of glomus jugulare tumor"

Báo cáo khoa học: "Radiosurgery for pituitary adenomas: evaluation of its efficacy and safety"

Báo cáo y học: "A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin® for treatment of osteoarthritis of the knee"

Báo cáo y học: " Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold"

Báo cáo y học: " The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial"
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.